SCHEMBL5581859

SCHEMBL5581859

CNc1ncc2c(-c3ccccc3Cl)cc(-c3ccc(C(=O)O)cc3)c(OC)c2n1

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAP4K4 O95819 1/20 0.47
CSNK2A1 P68400 6/20 0.46
CSNK2A2 P19784 2/20 0.44
CSNK2B P67870 2/20 0.44
LRRK2 Q5S007 1/20 0.42
RORC P51449 2/20 0.39
IGF1R P08069 2/20 0.39
KDM4E B2RXH2 2/20 0.39
PTK2 Q05397 2/20 0.39
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
GSK3A P49840 1/20 0.38
GSK3B P49841 1/20 0.38
EGLN1 Q9GZT9 1/20 0.38
ALDH1A1 P00352 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
DEGS1 O15121 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5581693 0.93 CSNK2A1 (0.45) MAP4K4CSNK2A1CSNK2A2CSNK2BLRRK2
SCHEMBL5582330 0.90 CSNK2A1 (0.48) MAP4K4CSNK2A1CSNK2A2CSNK2BPTK2
SCHEMBL5582267 0.90 CSNK2A1 (0.46) MAP4K4CSNK2A1CSNK2A2CSNK2BLRRK2
SCHEMBL5582010 0.88 CSNK2A2 (0.47) MAP4K4CSNK2A1CSNK2A2CSNK2BLRRK2
SCHEMBL5582325 0.88 KMO (0.43) MAP4K4CSNK2A1CSNK2A2CSNK2BLRRK2
SCHEMBL5582255 0.87 CSNK2A1 (0.43) MAP4K4CSNK2A1CSNK2A2CSNK2BLRRK2
SCHEMBL5582212 0.86 CSNK2A1 (0.49) MAP4K4CSNK2A1CSNK2A2CSNK2BLRRK2
SCHEMBL5582013 0.85 CSNK2A1 (0.51) CSNK2A1CSNK2A2CSNK2BLRRK2
SCHEMBL5582184 0.85 CSNK2A1 (0.43) CSNK2A1CSNK2A2CSNK2BPTK2GSK3A
SCHEMBL5582036 0.84 PTPN11 (0.43) MAP4K4CSNK2A1CSNK2A2CSNK2BLRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225308-A1 2-Amino Quinazoline Derivative KYOWA HAKKO KOGYO CO.,LTD. (JP) 2007-09-27 US disclosed
EP-1726584-A1 2-AMINOQUINAZOLINE DERIVATIVE KYOWA HAKKO KOGYO CO., LTD. (JP) 2006-11-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070225308-A1 2-Amino Quinazoline Derivative AGTR2, ABL1, AGTR1 MAP4K4 1461/4885CSNK2A1 602/4885CSNK2A2 467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.